Floatz logo

PEGFILGRASTIM

Acute Myeloid Leukemia With BCR-ABL1

M.D. Anderson Cancer Centerprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Acute Myeloid Leukemia With BCR-ABL1 cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 2B
Blinatumomab
M.D. Anderson Cancer Center
Phase 2B
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2B
METHOTREXATE
M.D. Anderson Cancer Center
Phase 2B
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2CCC

View all 11 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →